Dimyristoylphosphatidylcholine | 83199-49-9

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 甘油磷脂
• 英文名称: Dimyristoylphosphatidylcholine
• 英文别名: 2-[[(2R)-2,3-di(tetradecanoyloxy)propoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
• CAS: 83199-49-9
• 化学式: C36H73NO8P+
• 分子量: 678.9
• InChiKey: CITHEXJVPOWHKC-UUWRZZSWSA-O

计算性质

• 辛醇/水分配系数(LogP)：
  11.4
• 重原子数：
  46
• 可旋转键数：
  36
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.94
• 拓扑面积：
  108
• 氢给体数：
  1
• 氢受体数：
  8

文献信息

• OPHTHALMIC PHARMACEUTICAL COMPOSITION, PREPARATION METHODS AND USES OF SAME
  申请人：Sophia Holdings, S.A. de C.V.

  公开号：EP4026538A1

  公开（公告）日：2022-07-13

  The present invention relates to ophthalmic compositions in the form of oil-in-water (O/W) nano-emulsions, and which mainly comprise propylene glycol and sodium hyaluronate. The invention also relates to preparation methods and uses of the artificial tear compositions.

  本发明涉及水包油（O/W）纳米乳剂形式的眼科组合物，其中主要包括丙二醇和透明质酸钠。本发明还涉及人工泪液组合物的制备方法和用途。
• Bi-directionally crosslinked liposomes and method of making same
  申请人：Verily Life Sciences LLC

  公开号：US10842746B1

  公开（公告）日：2020-11-24

  Disclosed herein are methods for producing bi-directionally crosslinked liposomes. The methods include the steps of: providing a lipid composition comprising a plurality of reactive lipids, wherein each of the reactive lipids comprises a reactive hydrophobic group, a reactive hydrophilic group, or a reactive hydrophilic group and a reactive hydrophobic group; forming an un-crosslinked liposome comprising the reactive lipids; and crosslinking at least a portion of the reactive hydrophobic groups or the reactive hydrophilic groups; thereby producing the bi-directionally crosslinked liposomes. Bi-directionally crosslinked liposomes and methods for delivering therapeutic and/or diagnostic agents to subjects using the liposomes are also described.

  本文公开了生产双向交联脂质体的方法。这些方法包括以下步骤：提供包含多种活性脂质的脂质组合物，其中每种活性脂质包含一个活性疏水基团、一个活性亲水基团或一个活性亲水基团和一个活性疏水基团；形成包含活性脂质的未交联脂质体；交联至少一部分活性疏水基团或活性亲水基团；从而生产双向交联脂质体。此外，还描述了双向交联脂质体和使用该脂质体向受试者递送治疗和/或诊断制剂的方法。
• COMPOSITIONS AND METHODS FOR TREATMENT OF TUMORS AND METASTATIC DISEASES
  申请人：——

  公开号：US20020039571A1

  公开（公告）日：2002-04-04

  Compositions and methods are provided which can be utilized in active immunization as a prophylactic treatment or a therapeutic treatment for tumors. The compositions are employed as injectable tumor vaccines or as preparations for intratumoral administration and are capable of stimulating immune responses to specific tumor antigens. The tumor vaccines are composed of an antigenic cellular material including a plurality of inactivated tumor cells or tumor cell portions, a depot material, and an immunostimulant adsorbed to the depot material. The depot material with absorbed immunostimulant is mixed with the tumor cells or tumor cell portions to form the vaccine compositions. The preparations for intratumoral administration include the depot material adsorbed immunostimulant without the antigenic cellular material. The immunostimulant adsorbed to the depot material permits release of biologically active quantities of the immunostimulant over a period of time rather than all at once.

  所提供的组合物和方法可用于主动免疫，作为肿瘤的预防性治疗或治疗性治疗。这些组合物可用作可注射的肿瘤疫苗或用于肿瘤内给药的制剂，并能激发对特定肿瘤抗原的免疫反应。肿瘤疫苗由抗原细胞材料（包括多个灭活的肿瘤细胞或肿瘤细胞部分）、去势材料和吸附在去势材料上的免疫刺激剂组成。吸附了免疫刺激剂的去势材料与肿瘤细胞或肿瘤细胞部分混合，形成疫苗组合物。用于瘤内给药的制剂包括吸附了免疫刺激剂的去势材料，但不包括抗原细胞材料。吸附在去势材料上的免疫刺激剂可在一段时间内释放生物活性量的免疫刺激剂，而不是一次性全部释放。
• Compositions and methods for treatment of tumors and metastatic diseases
  申请人：Frank W. Falkenberg

  公开号：US20020176845A1

  公开（公告）日：2002-11-28

  Compositions and methods are provided which can be utilized in active immunization as a prophylactic treatment or a therapeutic treatment for tumors. The compositions are employed as injectable tumor vaccines or as preparations for intratumoral administration and are capable of stimulating immune responses to specific tumor antigens. The tumor vaccines are composed of an antigenic cellular material including a plurality of inactivated tumor cells or tumor cell portions, a depot material, and an immunostimulant adsorbed to the depot material. The depot material with absorbed immunostimulant is mixed with the tumor cells or tumor cell portions to form the vaccine compositions. The preparations for intratumoral administration include the depot material adsorbed immunostimulant without the antigenic cellular material. The immunostimulant adsorbed to the depot material permits release of biologically active quantities of the immunostimulant over a period of time rather than all at once.

  所提供的组合物和方法可用于主动免疫，作为肿瘤的预防性治疗或治疗性治疗。这些组合物可用作可注射的肿瘤疫苗或用于肿瘤内给药的制剂，并能激发对特定肿瘤抗原的免疫反应。肿瘤疫苗由抗原细胞材料（包括多个灭活的肿瘤细胞或肿瘤细胞部分）、去势材料和吸附在去势材料上的免疫刺激剂组成。吸附了免疫刺激剂的去势材料与肿瘤细胞或肿瘤细胞部分混合，形成疫苗组合物。用于瘤内给药的制剂包括吸附了免疫刺激剂的去势材料，但不包括抗原细胞材料。吸附在去势材料上的免疫刺激剂可在一段时间内释放生物活性量的免疫刺激剂，而不是一次性全部释放。
• Particulate-stabilized injectable pharmacutical compositions of posaconazole
  申请人：Witchey-Lakshmanan Leonore

  公开号：US20090226527A1

  公开（公告）日：2009-09-10

  The present invention provides formulations useful for treating infections, in particular, formulations that include the active pharmaceutical ingredient Posaconazole in an injectable suspension of particles that is stable when subjected to terminal sterilization. Preferred median particle sizes of between 1.5 and 3.0 microns are found to result in superior pharmacokinetic characteristics-displayed in FIG. 7.

表征谱图